![GILEAD SCIENCES, INC. [GILD] reports annual net loss of $5.6 billion](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FGILD.png&w=1200&q=75)
GILEAD SCIENCES, INC. [GILD] has reported a net loss of $5.6 billion for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $27.1 billion
Based in FOSTER CITY, California, GILEAD SCIENCES, INC. operates in the MANUFACTURING sector.
In the annual report for the fiscal year ending December 31, 2023, Gilead Sciences Inc. reported total revenues of $27.1 billion, slightly lower than the $27.3 billion reported in the previous year, indicating a marginal decrease in revenue. The cost of goods sold for the year was $6.5 billion, higher than the $6.6 billion reported in the prior year.
Operating income for the year was $7.6 billion, showing an increase from the $7.3 billion reported in the previous year. The company reported a net income of $5.6 billion for the current year, up from $4.6 billion in the previous year.
The basic earnings per share attributable to Gilead were $4.54 for the current year, compared to $3.66 in the previous year. The diluted earnings per share for the current year were $4.50, up from $3.64 in the prior year.
In terms of product sales, total revenues from sales were $26.9 billion for the current year, slightly lower than the $27.0 billion reported in the previous year. Additionally, royalty, contract, and other revenues totaled $182 million for the current year, down from $299 million in the previous year.
Overall, Gilead Sciences Inc. showed improved financial performance in terms of operating income and net income for the fiscal year ending December 31, 2023, despite a slight decrease in total revenues compared to the previous year.
Also Read: